BioCryst sues Annora, Hetero and Camber in Delaware over generic ORLADEYO

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is suing four companies in the U.S. District Court for the District of Delaware over a proposed generic version of ORLADEYO, its hereditary angioedema drug. The defendants are Annora Pharma Private Limited, Hetero Labs Limited, Hetero USA, Inc. and Camber Pharmaceuticals, Inc. The 10-Q filed August 5, 2026 calls them collectively the Defendants and gives no case number.

BioCryst filed the suit on March 10, 2025, and supplemented it with a First Amended Complaint in December 2025. It followed two Paragraph IV notices of certification from Annora, one in January 2025 and one in January 2026.

The case

The notice letters say Annora has submitted an Abbreviated New Drug Application to the FDA seeking approval to market a generic ORLADEYO before four patents in the FDA's Orange Book expire. The first letter covers U.S. Patent Nos. 10,662,160, 11,117,867 and 11,618,733. The second adds U.S. Patent No. 12,344,585. The letters allege that these patents, which expire in May 2040, are invalid, unenforceable or will not be infringed.

BioCryst's complaint asserts infringement of the four patents, arising from Annora's filing. It seeks equitable relief barring the Defendants from infringing, and an order that any FDA approval of the application take effect no earlier than the patents expire, including any regulatory extensions. Six other ORLADEYO Orange Book patents, which expire in 2035, are not challenged in the notice letters. They are U.S. Patent Nos. 10,125,102, 10,329,260, 10,689,346, 11,230,530, 11,708,333 and 12,116,346.

Defendants

The defendants are Annora Pharma Private Limited, Hetero Labs Limited, Hetero USA, Inc. and Camber Pharmaceuticals, Inc. The 10-Q names no individuals. BioCryst is the plaintiff, and the 10-Q does not mention counterclaims.

Where it stands

The 10-Q says the matter is in the early stages of litigation. It reports no trial date, no ruling and no settlement. The company says it intends to defend its intellectual property rights protecting ORLADEYO vigorously. It adds that no assessment can be made of the likely outcome or whether the matter will be material. For that reason, it says, an estimate of the potential loss, or range of loss, is not possible at this time.

The filing says the NCE-1 date for ORLADEYO was in December 2024. Under the process it describes, a third party may file an application containing a Paragraph IV certification four years after the original product approval. It also says additional third parties could challenge BioCryst's patents.

Why it matters to shareholders

ORLADEYO is the product at stake. For the three months ended June 30, 2026, the 10-Q reports a $14.7 million increase in ORLADEYO revenue compared with the same period of 2025, excluding the European business that BioCryst sold on October 1, 2025. It attributes the increase to a net price increase and higher volume of direct sales. The company also says it anticipates that the global commercial market for ORLADEYO has the potential to reach a peak of $1 billion in annual net revenues. It bases that on proprietary analyses and over five years of commercialization experience with ORLADEYO, and it notes that these expectations are subject to numerous risks and uncertainties.

A risk factor adds that BioCryst owes royalties to RPI and OMERS on certain ORLADEYO revenues under its royalty purchase agreements, which may reduce the profitability of the product. The royalty purchase agreements date from 2020 and 2021. The 10-Q does not say whether insurance covers litigation costs.

Report an error

Companies in this story

BCRXBioCryst Pharmaceuticals, Inc.NASDAQ · United StatesOpen the desk